Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949230 · ClinicalTrials.gov registry record
A Retrospective Study of COVID-19 Treatments
A clinical trial of COVID-19 and SARS CoV 2 Infection, sponsored by ProgenaBiome.
- Completed
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT04949230: Completed study of COVID-19 and SARS CoV 2 Infection, sponsored by ProgenaBiome.
NCT04949230 is a study of COVID-19 and SARS CoV 2 Infection that has completed, run by ProgenaBiome. The registered enrollment target is 300 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04949230, a study of COVID-19 and SARS CoV 2 Infection, has completed, sponsored by ProgenaBiome.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.
Primary Outcome
Answers given by subjects on their recovery from COVID-19
Conditions Studied
Interventions
- OTHER No Intervention Used
Study Locations (1)
California
- Ginger Aurella - Ventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2024-02-15 |
What the finished NCT04949230 record still lists
NCT04949230 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 8 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which No Intervention Used is the first listed.
NCT04949230 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04949230 about?
NCT04949230 is a clinical study titled "A Retrospective Study of COVID-19 Treatments". Surveys administered to subjects who have recovered from COVID-19 to assess how effective their treatment was.
What is the current status of trial NCT04949230?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2021-02-19. Estimated completion is 2024-02-15.
What conditions does trial NCT04949230 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection, COVID-19 Respiratory Infection, COVID-19 Pneumonia, COVID-19 Acute Respiratory Distress Syndrome.
What interventions are being tested in trial NCT04949230?
The interventions under investigation include: No Intervention Used (OTHER).
Who is sponsoring clinical trial NCT04949230?
This trial is sponsored by ProgenaBiome, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04949230 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04949230's enrollment target sits among peer trials
300 139th of 298 higher than 157 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI